New treatment options for patients with metastatic prostate cancer

Netherlands Journal of Medicine

Volumn 71, Issue 6, 2013, Pages 290-294

  Snoeks, L L ^a   Ogilvie, A C ^a   van Haarst, E P ^a   Siegert, C E H ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Abiraterone; Cabazitaxel; CRPC; Enzalutamide; Prostate cancer

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; SIPULEUCEL T;

ANTIANDROGEN THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONVULSION; CYTOTOXICITY; DIARRHEA; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIUM; TAXOIDS; TISSUE EXTRACTS;

EID: 84882271072     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Cremers RG, Karim-Kos HE, Houterman S, et al. Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006. Eur J Cancer. 2010;46:2077-87.
2. Omlin A, de Bono JS. Therapeutic options for advanced prostate cancer: 2011 update. Curr Urol Rep. 2012;13:170-8.
3. CBO richtlijn Prostaatcarcinoom: diagnostiek en behandeling. 2007.
4. Moorselaar RJA van, Piet AHM, Gerritsen PWR. Prostaatkanker. In: Wymenga ANM, Coebergh JWW, Maas HAAM, Schouten HC, redacteuren. Handboek Kanker bij ouderen. 1e dr. Hfdst 19. Enschede: De Tijdstroom Uitgeverij; 2012. p. 241-8.
5. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15:4792-8.
6. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011;103:1665-75.
7. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26:1148-59.
8. Bergman AM, Kerst JM. Ontwikkelingen in de systemische behandeling van castratieresistent prostaatkanker. Therapie Actueel. 2011;4:160-8.
9. Tannock IF, Wit R de, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
10. Mason M, Freemantle N, Parnaby A, Hogberg D. No conclusive evidence from randomised controlled trials to inform second-line treatment options survival and clinical benefits, in patients with metastatic hormone-refractory prostate cancer (MHRPC), previously treated with docetaxel. Ann Oncol. 2010;21(suppl 8): abstract 967.
11. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-54.
12. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
13. Ryan CJ, Smith MR, de Bono JS et al. COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138-48.
14. Fizazi K, Scher HI, Molina A, et al. COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-92.
15. Scher HI, Fizazi K, Saad F, et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-97.
16. Kantoff PW, Higano CS, Shore ND, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
17. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol. 30, 2012;suppl: Abstract LBA4512.
18. Sartor OA, Fitzpatrick JM. Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int. 2012;110:328-35.